Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Stefan Hohaus is active.

Publication


Featured researches published by Stefan Hohaus.


British Journal of Haematology | 2000

In vivo depletion of B cells using a combination of high‐dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non‐Hodgkin's lymphoma

M. T. Voso; Gitta Pantel; Mirjam Weis; Petra Schmidt; Simona Martin; Marion Moos; Anthony D. Ho; Rainer Haas; Stefan Hohaus

We performed a pilot study including rituximab (Mabthera; IDEC‐C2B8, Hoffmann‐La Roche) with a sequential high‐dose therapy protocol in 15 patients with follicular and three patients with mantle cell lymphoma and studied the potential of the chemoimmunotherapy to induce depletion of malignant B cells in vivo. Our treatment protocol included induction with three cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy, followed by peripheral blood stem cell (PBSC) mobilization using high‐dose cytosine arabinoside (2 g/m2 every 12 h, days 1 and 2) and mitoxantrone (10 mg/m2, days 2 and 3) (HAM), preceeded by rituximab (375 mg/m2). The proportion of CD19+ B cells in blood and bone marrow decreased from 1·2 ± 0·4% to 0·13 ± 0·1% (P = 0·01) and from 2·7 ± 0·8% to 0·8 ± 0·5% (P = 0·03) respectively. The number of t(14;18)‐positive cells in blood and bone marrow progressively decreased with treatment, as assessed by the quantitative real‐time PCR assay in four patients. Conversion to PCR‐negativity was achieved in the peripheral blood (PB) of seven informative patients. Leucaphereses were performed during the granulocyte colony‐stimulating factor (G‐CSF)‐supported leucocyte recovery phase. In 17 of 18 patients, a median of 15·1 × 106 CD34+ cells/kg body weight (BW) could be harvested by a single procedure for enrichment by an immunomagnetic method. Leucapheresis products contained 51·3 ± 28·8 × 104 CD19+ B cells/kg BW (mean) and were t(14;18) PCR negative in all seven informative patients. These data compare favourably with results obtained in patients treated with the same regimen without rituximab. The high‐dose therapy (n = 12 patients), including total body irradiation (14·4 Gy) and cyclophosphamide (200 mg/kg BW), was also preceeded by rituximab. Recovery of neutrophils to > 0·5 × 109/l and of platelets to > 20 × 109/l required a median of 13·5 and 11·5 d (range 11–24 and 9–24 d) respectively. In conclusion, the addition of the CD20 antibody to chemotherapy ensured tumour depletion in vivo and allowed the collection of PBSCs devoid of tumour cells and with conserved engraftment capability.


Clinical Cancer Research | 2005

Glutathione S-transferase P1 Genotype and Prognosis in Hodgkin's Lymphoma

Stefan Hohaus; Annalisa Di Ruscio; Annalaura Di Febo; Giuseppina Massini; Francesco D'Alo'; Francesco Guidi; Giovanna Mansueto; Maria Teresa Voso; Giuseppe Leone

Purpose: Glutathione S-transferase P1 (GSTP1) is a member of the GST enzyme superfamily that is important for the detoxification of several cytotoxic drugs and their by-products. A single nucleotide polymorphism results in the substitution of isoleucine (Ile) to valine (Val) at codon 105, causing a metabolically less active variant of the enzyme. We assessed the impact of the GSTP1 codon 105 genotype on treatment outcome in patients with Hodgkins lymphoma. Experimental Design: The Ile105Val polymorphism in the GSTP1 gene was analyzed using a PCR-RFLP technique. Ninety-seven patients with Hodgkins lymphoma were included and associations with patient characteristics and treatment outcome were analyzed. Results: The GSTP1 Ile105Val polymorphism was associated in a dose-dependent fashion with an improved failure-free survival in patients with Hodgkins lymphoma (P = 0.02). The probability of 5-year survival for patients homozygous for the 105Val/105Val GSTP1 genotype was 100%, for heterozygous patients 74% (95% confidence interval, 56-85), and for patients homozygous for the 105Ile/105Ile genotype 43% (95% confidence interval, 23-61). The Cox multivariate analysis showed that GSTP1 codon 105 genotype was an independent prognostic factor. Conclusions: The GSTP1 genotype predicts clinical outcome in patients with Hodgkins lymphoma.


Journal of Clinical Oncology | 2010

Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin

Stefan Hohaus; Giuseppina Massini; Manuela Giachelia; Barbara Vannata; Valentina Bozzoli; Annarosa Cuccaro; Francesco D'Alo'; Luigi Maria Larocca; Reinier A.P. Raymakers; Dorine W. Swinkels; Maria Teresa Voso; Giuseppe Leone

PURPOSE Cytokines play a pivotal role in Hodgkins lymphoma (HL). Because interleukin-6 (IL-6) induces expression of hepcidin, one of the principal regulators of iron metabolism, we studied the contribution of hepcidin in anemia in HL at diagnosis. PATIENTS AND METHODS Plasma samples from 65 patients with HL were analyzed for hepcidin levels using a combination of weak cation exchange chromatography and time-of-flight mass spectrometry; cytokine levels were analyzed using enzyme-linked immunosorbent assays and parameters of iron metabolism and acute-phase reaction. RESULTS Hepcidin plasma levels were significantly higher in HL patients when compared with controls, independent of the presence of anemia (P = .001). In the subset of patients with anemia, hepcidin levels inversely correlated with hemoglobin levels (P = .01). Analyzing parameters of iron metabolism, hepcidin levels showed a positive correlation with ferritin (P < .001) and an inverse correlation to iron and iron-binding capacity. Hepcidin strongly correlated to IL-6 levels (P < .001) but not to IL-10 or thymus and activation-regulated cytokine (TARC)/chemokine (C-C motif) ligand 17 (CCL17) levels. In a multivariate regression analysis, IL-6 and fibrinogen levels were independently associated with hepcidin. Higher hepcidin levels were observed in patients with more aggressive disease characteristics: stage IV disease (P = .01), presence of B symptoms (P = .03), and International Prognostic Score > 2 (P = .005). CONCLUSION Our findings suggest that in HL, hepcidin is upregulated by IL-6. Elevated hepcidin levels result in iron restriction and signs of anemia of chronic inflammation, although hepcidin-independent mechanisms contribute to development of anemia in HL.


Clinical Cancer Research | 2011

The viral load of Epstein-Barr virus (EBV)-DNA in Peripheral Blood Predicts for Biological and Clinical Characteristics in Hodgkin Lymphoma

Stefan Hohaus; Rosaria Santangelo; Manuela Giachelia; Barbara Vannata; Giuseppina Massini; Annarosa Cuccaro; Maurizio Martini; Valeriana Cesarini; Tonia Cenci; Francesco D'Alo'; Maria Teresa Voso; Giovanni Fadda; Giuseppe Leone; Luigi Maria Larocca

Purpose: The Epstein–Barr virus (EBV) is present in the malignant Hodgkin/Reed–Sternberg (HRS) cells of 20% to 40% cases of Hodgkin lymphoma (HL) in Western countries. We were interested in the detection and quantification of cell-free plasma EBV-DNA as an indicator of biological and clinical characteristics in EBV-associated HL. Experimental Design: EBV was detected in peripheral blood compartments (whole blood, plasma, and mononuclear cells) at diagnosis by real-time PCR for the EBNA (EB nuclear antigen) region (n = 93) and in HRS cells by in situ hybridization for EBV-encoded small RNAs (EBER; n = 63). These data were correlated to histological and clinical characteristics, EBV serology, circulating cell-free DNA, and interleukin (IL)-6 levels. Results: Detection of EBV-DNA in plasma had a high specificity (90%), but a relatively low sensitivity (65%) to predict for EBV association. The viral load was higher in patients with advanced stage disease, older age in the presence of B-symptoms, and international prognostic score more than 2. The presence of EBV in HRS cells and higher plasma EBV-DNA copy numbers correlated to an increased frequency of tumor-infiltrating CD68+ macrophages in lymph node biopsies. Plasma EBV-DNA load correlated to circulating cell-free DNA and IL-6 levels, and inversely correlated to lymphocyte counts and EBNA1 antibody titers. Conclusion: Although the presence of EBV-DNA in peripheral blood cannot be regarded as a surrogate marker for EBER, the plasma EBV-DNA load at HL diagnosis is an indicator of disease activity and biological characteristics associated with negative prognosis. Moreover, the inverse correlation to EBNA1 antibody titers and lymphocyte counts may indicate a reduction in immunosurveillance, favoring the expansion of EBV-HRS cells in HL. Clin Cancer Res; 17(9); 2885–92. ©2011 AACR.


Bone Marrow Transplantation | 1998

Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells

Stefan Hohaus; H Martin; B Wassmann; G Egerer; U Haus; L Färber; Kj Burger; H. Goldschmidt; D Hoelzer; R Haas

The availability of hematopoietic growth factors has greatly facilitated the mobilization and collection of peripheral blood stem cells (PBSC). It was the aim of this double-blind study to compare the PBSC-mobilizing efficacy of recombinant human G-CSF and GM-CSF when administered post-chemotherapy. Twenty-six patients with relapsed Hodgkin’s disease were included in the study. Their median age was 31 years (range, 22–59) and 14 patients were males and 12 were females. Patients were pretreated with a median of eight cycles of cytotoxic chemotherapy, while 18 patients had undergone extended field irradiation. The patients received dexamethasone 24 mg days 1–7, melphalan 30 mg/m2 day 3, BCNU 60 mg/m2 day 3, etoposide 75 mg/m2 days 4–7, Ara-C 100 mg/m2 twice daily days 4–7 (Dexa-BEAM). Twelve patients were randomized to receive 5 μg/kg/day G-CSF and 14 patients to receive 5 μg/kg/day GM-CSF, both administered subcutaneously starting on day 1 after the end of Dexa-BEAM. Primary endpoints of the study were the number of CD34+ cells harvested per kg body weight on the occasion of six consecutive leukaphereses and the time needed for hematological reconstitution following autografting. Twenty-one patients completed PBSC collection, and six patients of the G-CSF group and nine of the GM-CSF group were autografted. No difference was observed with respect to the median yield of CFU-GM and CD34+ cells: 32.5 × 104/kg vs 31.3 × 104/kg CFU-GM, and 7.6 × 106/kg vs 5.6 × 106/kg CD34+ cells, for G-CSF and GM-CSF, respectively (U test, P = 0.837 and 0.696). High-dose chemotherapy consisted of cyclophosphamide 1.7 g/m2 days 1–4, BCNU 150 mg/m2 days 1–4, etoposide 400 mg/m2 days 1–4. All patients transplanted with more than 5 × 106 CD34+ cells/kg had a rapid platelet recovery (20 × 109/l) between 6 and 11 days and neutrophil recovery (0.5 × 109/l) between 9 and 16 days, while patients transplanted with less than 5 × 106/kg had a delayed reconstitution, regardless of the kind of growth factor used for PBSC mobilization. In conclusion, our data indicate that in patients with Hodgkin’s disease G-CSF and GM-CSF given after salvage chemotherapy appear to be not different in their ability to mobilize PBSC resulting in a similar time needed for hematological reconstitution when autografted following high-dose therapy.


British Journal of Cancer | 2006

Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia

Alessandra Scardocci; Francesco Guidi; Francesco D'Alo'; Daniela Gumiero; Emiliano Fabiani; Annalisa Diruscio; Maurizio Martini; Luigi Maria Larocca; Marcella Zollino; Stefan Hohaus; Giuseppe Leone; Maria Teresa Voso

BRCA1 plays a pivotal role in the repair of DNA damage, especially following chemotherapy and ionising radiation. We were interested in the regulation of BRCA1 expression in acute myeloid leukaemia (AML), in particular in therapy-related forms (t-AML). Using real-time PCR and Western blot, we found that BRCA1 mRNA was expressed at barely detectable levels by normal peripheral blood granulocytes, monocytes and lymphocytes, whereas control BM-mononuclear cells and selected CD34+ progenitor cells displayed significantly higher BRCA1 expression (P=0.0003). Acute myeloid leukaemia samples showed heterogeneous BRCA1 mRNA levels, which were lower than those of normal bone marrows (P=0.0001). We found a high frequency of hypermethylation of the BRCA1 promoter region in AML (51/133 samples, 38%), in particular in patients with karyotypic aberrations (P=0.026), and in t-AML, as compared to de novo AML (76 vs 31%, P=0.0002). Examining eight primary tumour samples from hypermethylated t-AML patients, BRCA1 was hypermethylated in three of four breast cancer samples, whereas it was unmethylated in the other four tumours. BRCA1 hypermethylation correlated to reduced BRCA1 mRNA (P=0.0004), and to increased DNA methyltransferase DNMT3A (P=0.003) expression. Our data show that reduced BRCA1 expression owing to promoter hypermethylation is frequent in t-AML and that this could contribute to secondary leukaemogenesis.


Bone Marrow Transplantation | 2000

Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).

Mt Voso; S Martin; Stefan Hohaus; Alhossain Abdallah; Rf Schlenk; A. D. Ho; Rainer Haas

This is a report on 111 patients with advanced stage follicular lymphoma who where autografted using PBSC. Seventy patients were enrolled in first remission, whereas 41 were treated in second or higher remission. High-dose therapy consisted of total body irradiation plus cyclophosphamide in 103 patients, while eight patients received BEAM (carmustine, etoposide, cytosine-arabinoside, melphalan). Autografts contained 8.1 ± 0.6 × 106 CD34+ cells/kg body weight. At a median follow-up of 44.2 months from PBSCT (range 4.9–77.4 months), 93 patients are alive, with a probability of overall and relapse-free survival (RFS) of 83% and 64%, respectively. A significantly higher probability of relapse was associated with male gender, involvement of more than eight lymph node areas, extra-nodal manifestations other than bone marrow and PBSCT performed in second or higher remission. In the latter group of patients, previous radiotherapy was associated with poor prognosis. The relevance of chemosensitivity as a prognostic factor was reflected by a better RFS in patients who had achieved complete remission at the time of PBSC mobilization. In a multivariate analysis, involvement of eight or more lymph nodes and high-dose therapy performed in second or higher remission were independent prognostic factors. Bone Marrow Transplantation (2000) 25, 957–964.


Annals of Oncology | 2009

Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas

Stefan Hohaus; Manuela Giachelia; Giuseppina Massini; Giovanna Mansueto; Barbara Vannata; Valentina Bozzoli; Marianna Criscuolo; Francesco D'Alo'; Maurizio Martini; Luigi Maria Larocca; Maria Teresa Voso; Giuseppe Leone

BACKGROUND Levels of cell-free circulating DNA have been correlated to clinical characteristics and prognosis in patients with cancers of epithelial origin, while there are no data on patients with B-lymphoproliferative diseases. PATIENTS AND METHODS Cell-free DNA levels in the plasma samples of 142 patients with lymphomas [45 with Hodgkins lymphoma (HL), 63 with diffuse large B-cell non-Hodgkins lymphoma (DLBCL), 24 with follicular, and 10 with mantle cell non-Hodgkins lymphoma (NHL)] at diagnosis and of 41 healthy individuals were determined using a quantitative PCR for the beta-globin gene. RESULTS Levels of circulating DNA in patients with HL, DLBCL, and mantle cell NHL were significantly higher than in controls (P < 0.01 for all). Increased levels of plasma DNA were associated with advanced stage disease, presence of B-symptoms, elevated lactate dehydrogenase levels, and age >60 years (P = 0.009; <0.0001; <0.0001; 0.04, respectively). In HL, histological signs of necrosis and grade 2 type of nodular sclerosis were associated with increased plasma DNA. Elevated plasma DNA levels were associated with an inferior failure-free survival in patients with HL (P = 0.01) and DLBCL (P = 0.03). CONCLUSION Quantification of circulating DNA by real-time PCR at diagnosis can identify patients with elevated levels that are associated with disease characteristics indicating aggressive disease and poor prognosis.


International Journal of Cancer | 2001

Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients

Alexander Seute; Hans-Peter Sinn; Richard F. Schlenk; Robert Emig; Diethelm Wallwiener; Eva-Maria Grischke; Stefan Hohaus; Hartmut Döhner; Rainer Haas; Martin Bentz

Little is known about the prognostic impact of chromosome aberrations in breast cancer. The aim of our study was to determine whether genomic aberrations of prognostic relevance can be identified in the context of a clinical study using molecular cytogenetics. Paraffin‐embedded tumor samples of 44 patients with high‐risk stage II/III breast cancer were analyzed by comparative genomic hybridization. All patients received identical therapy including dose‐escalated chemotherapy followed by peripheral blood stem cell transplantation. The most frequent chromosomal aberrations were gains on chromosome arms 17q (24 cases), 1q (21 cases), 8q (17 cases), 20q (13 cases), 6p (9 cases) as well as losses on chromosome arms 13q (25 cases), 11q (20 cases), 5q (11 cases), 6q (11 cases), 9p (10 cases), 18q (10 cases), 8p (9 cases) and 16q (9 cases). In univariate analysis, the correlation with the clinical outcome revealed a higher risk for patients with tumors exhibiting 13q losses and a reduced risk for tumors exhibiting 16q losses (p = 0.020), 6q losses (p = 0.041) and estrogen‐receptor positivity (0.051). In multivariate analysis using the Cox model, only the loss of 16q exhibited borderline significance (p = 0.065). These data show that comparative genomic hybridization can be performed in the context of a clinical trial. In our subgroup of high‐risk breast cancer patients, chromosomal aberrations were valuable prognostic parameters.


Leukemia & Lymphoma | 2013

High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study

Luana Fianchi; Marianna Criscuolo; Massimo Breccia; Luca Maurillo; Flavia Salvi; Pellegrino Musto; Giovanna Mansueto; Gianluca Gaidano; C. Finelli; A Aloe-Spiriti; Santini; Michele Mario Greco; Stefan Hohaus; Giuseppe Leone; Maria Teresa Voso

1 Istituto di Ematologia, Universit à Cattolica del Sacro Cuore, Roma, Italy, 2 Dipartimento di Biotecnologie Cellulari ed Ematologia, Universit à La Sapienza, Roma, Italy, 3 Istituto di Ematologia, Fondazione Policlinico Tor Vergata, Roma, Italy, 4 Ematologia, A.O. SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, 5 Dipartimento di Onco-Hematology, IRCCS, Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy, 6 Divisione di Ematologia, Dipartimento di Medicina Traslazionale, Universit à del Piemonte Orientale Amedeo Avogadro, Novara, Italy, 7 S.Orsola-Malpighi University Hospital, Department of Hematology and Oncological Sciences “Ser à gnoli”, Bologna, Italy, 8 Dipartimento di Ematologia, Ospedale Sant ’ Andrea, Universit à La Sapienza, Roma, Italy and 9 Ematologia, AOU Careggi, Universit à di Firenze, Firenze, Italy

Collaboration


Dive into the Stefan Hohaus's collaboration.

Top Co-Authors

Avatar

Giuseppe Leone

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Maria Teresa Voso

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Francesco D'Alo'

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Luigi Maria Larocca

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Emiliano Fabiani

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Francesco Guidi

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Giuseppina Massini

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Manuela Giachelia

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Luana Fianchi

Catholic University of the Sacred Heart

View shared research outputs
Top Co-Authors

Avatar

Maria Chiara Tisi

Catholic University of the Sacred Heart

View shared research outputs
Researchain Logo
Decentralizing Knowledge